VISION: Retham Technologies™ seeks to revolutionize the diagnosis and management of Heparin induced thrombocytopenia (HIT).

MISSION: Retham Technologies™ will develop a platelet-activation based HIT IVD test, HITDx™, for accurate and timely HIT diagnosis.  HITDx™ will couple patented technology based on PF4-treated platelets with a technically simple endpoint and is expected to decreases morbidity, save lives and lower the cost of care for HIT-suspected patients.

ABOUT US

Retham Technologies™ LLC was established in 2017 to translate discoveries from the BloodCenter of Wisconsin into life-saving in vitro diagnostic (IVD) assays that provide earlier and more accurate in-hospital diagnosis of Heparin-induced Thrombocytopenia (HIT).

HIT is a serious adverse reaction to the blood thinner heparin. It is characterized by a drop in platelet count (thrombocytopenia) and in ~1/3rd of cases, causes blood clotting (thrombosis) that can result in life-and-limb threatening consequences such as amputation, stroke and death.  The diagnosis of HIT is challenging.  A family of easy-to-run tests called PF4 ELISAs is performed in the hospital laboratory but have high false positive rates, i.e. many patients positive for antibodies to PF4:polyanion complexes do not have clinical HIT.  A second test, the Serotonin release assay (SRA), is considered the “gold-standard” test for HIT; but, it is performed only at a handful of laboratories nationally on a small fraction of suspected cases due to technical complexity, cost and turnaround time concerns. Thus, >90% of HIT suspected patients are currently managed using PF4 ELISAs, and thousands of patients receive costly non-heparin anticoagulant therapy due to “false positive” diagnoses.  These alternative anticoagulants have a worse bleeding risk profile relative to heparin often resulting in severe or fatal hemorrhage.

 

Groundbreaking research conducted at the BloodCenter of Wisconsin in Drs. Padmanabhan and Aster’s laboratory suggests a new paradigm by which pathogenic HIT antibodies cause platelet activation in HIT.  Based on this research, Retham Technologies™ is developing HITDx™, a platelet activation-based IVD assay for early and accurate near-patient HIT diagnosis that is expected to facilitate timely and appropriate therapy leading to better outcomes.

CONTACT US

Retham Technologies LLC
1225 Discovery Pkwy

Wauwatosa, WI 53226

E-mail: retham@rethamtechnologies.com

 

© 2018 Retham Technologies™, LLC